BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

BACKGROUND: Although pazopanib treatment has become the standard chemotherapy in salvage setting for metastatic sarcoma patients, most patients progress after pazopanib treatment in 4 to 6 months. After failure to pazopanib, patients have limited options for treatment. Therefore, subsequent therapy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Kim, Hee Kyung, Kim, Sun Young, Lee, Su Jin, Kang, Mihyeon, Kim, Seung Tae, Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Lee, Dong Woo, Park, Woong Yang, Kim, Sung Joo, Park, Se Hoon, Lee, Jeeyun
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2016
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4907899/
https://ncbi.nlm.nih.gov/pubmed/27267837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2016.03.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados